Dr. Jason Farrell Skenazy, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 935 Highland Blvd, Bozeman, MT 59715 Phone: 406-414-5300 |
Dr. James Bruce Robertson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 711 W Main St, Bozeman, MT 59715 Phone: 406-551-2306 Fax: 855-544-7367 |
Gregory Pritham, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 935 Highland Blvd Ste 2160, Bozeman, MT 59715 Phone: 406-414-5300 |
John R Gannon, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 935 Highland Blvd Ste 2160, Bozeman, MT 59715 Phone: 406-414-5300 |
News Archive
Two dozen corporate leaders on Sunday signed a statement calling on 46 countries to lift restrictions on travelers who are living with HIV because the policies are discriminatory and bad for business, VOA's "Breaking News" blog reports.
Following ongoing advocacy campaigns spearheaded by AIDS Healthcare Foundation (AHF) that targeted several of the largest AIDS drug companies over their pricing and rebate policies for the nation's AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need, that the last remaining major AIDS drug company, Bristol-Myers Squibb (BMS) today announced an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide.
"A federal subsidy designed to make health insurance more affordable for laid-off workers has led to a doubling in the number of people who have opted to continue their former employer's coverage," USA Today reports. The subsidy, created by the federal stimulus package, covers 65 percent of COBRA premiums for workers who were laid off between Sept. 1, 2008 and the end of this year.
Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.
A study led by University of Cincinnati lipid metabolism researchers lends additional insight into how bacteria in the gut, or lack thereof, influences intestinal mast cells (MMC) activation and perhaps fat absorption.
› Verified 4 days ago